Imaging tau pathology in Alzheimer's disease with positron emission tomography: lessons learned from imaging-neuropathology validation studies.

"Declarations Competing interestsAM, MCW, TL, EA, NCF, KS and MS declare no competing interests. MEM served as a paid consultant of AVID Radiopharmaceuticals. Competing interests AM, MCW, TL, EA, NCF, KS and MS declare no competing interests. MEM served as a paid consultant of AVID Radiopharmaceuticals."

"Funding Open access funding provided by University of Gothenburg. AM is supported by Gamla Tjänarinnor. MS is supported by the Knut and Alice Wallenberg Foundation (Wallenberg Centre for Molecular and Translational Medicine; KAW2014.0363), the Swedish Research Council (2017–02869, 2021–02678 and 2021–06545), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (ALFGBG-813971 and ALFGBG-965326), the Swedish Brain Foundation (FO2021–0311) and the Swedish Alzheimer Foundation (AF-740191). MEM is supported by the National Institute on Aging (R01 AG054449, R01 AG073282, P30 AG062677, RF1 AG069052, U01 AG057195) and Florida Department of Health, Ed and Ethel Moore Alzheimer’s Disease Research Program (20A22). This work was in part undertaken at UCLH/UCL, which is funded in part by the Department of Health’s NIHR Biomedical Research Centres funding scheme."